Caris Life Sciences, Inc. SEC filings CAI

Caris Life Sciences, Inc. has 134 filings in SEC EDGAR's recent list, going back to Jun 10, 2024. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Caris Life Sciences, Inc. SEC filings
Form Description Filed Period
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 5, 2026 —
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Results of operations
Nov 4, 2026 Nov 4, 2026
4 Insider transaction Sep 23, 2026 Sep 22, 2026
144 Notice of proposed sale Sep 22, 2026 —
4 Insider transaction Sep 17, 2026 Sep 17, 2026
144 Notice of proposed sale Sep 17, 2026 —
8-K Current report
Regulation FD disclosure
Sep 14, 2026 Sep 14, 2026
4 Insider transaction Sep 4, 2026 Sep 3, 2026
144 Notice of proposed sale Sep 4, 2026 —
144 Notice of proposed sale Sep 3, 2026 —
144 Notice of proposed sale Aug 24, 2026 —
4 Insider transaction Aug 14, 2026 Aug 14, 2026
4 Insider transaction Aug 14, 2026 Aug 14, 2026
4 Insider transaction Aug 14, 2026 Aug 14, 2026
4 Insider transaction Aug 14, 2026 Aug 14, 2026
4 Insider transaction Aug 14, 2026 Aug 14, 2026
4 Insider transaction Aug 14, 2026 Aug 14, 2026
4 Insider transaction Aug 14, 2026 Aug 14, 2026
4 Insider transaction Aug 14, 2026 Aug 14, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 12, 2026 —
144 Notice of proposed sale Aug 7, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 7, 2026 —
10-Q Quarterly report Aug 5, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 5, 2026 Aug 5, 2026
144 Notice of proposed sale Aug 3, 2026 —
4 Insider transaction Jul 13, 2026 May 15, 2026
CERT Nyse texas certification Jun 16, 2026 —
8-A12B Form 8-a12b Jun 16, 2026 —
8-K Current report
Shareholder vote results
Jun 5, 2026 Jun 4, 2026
4 Insider transaction Jun 2, 2026 May 29, 2026
4 Insider transaction Jun 2, 2026 May 29, 2026
4 Insider transaction May 18, 2026 May 15, 2026
4 Insider transaction May 18, 2026 May 15, 2026
4 Insider transaction May 18, 2026 May 15, 2026
4 Insider transaction May 18, 2026 May 15, 2026
4 Insider transaction May 18, 2026 May 15, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) May 12, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 12, 2026 —
4 Insider transaction May 12, 2026 May 11, 2026
10-Q Quarterly report May 8, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
ARS Annual report to shareholders Apr 23, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 23, 2026 —
DEF 14A Proxy statement Apr 23, 2026 Jun 4, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 7, 2026 —
8-K Current report
Material agreement, Agreement ended, New debt
Apr 2, 2026 Apr 1, 2026
4 Insider transaction Mar 10, 2026 Mar 6, 2026
4 Insider transaction Mar 10, 2026 Mar 6, 2026
4 Insider transaction Mar 10, 2026 Mar 6, 2026
4 Insider transaction Mar 10, 2026 Mar 6, 2026
4 Insider transaction Mar 10, 2026 Mar 6, 2026
10-K Annual report Mar 3, 2026 Dec 31, 2025
4 Insider transaction Mar 2, 2026 Feb 26, 2026
4 Insider transaction Feb 27, 2026 Feb 26, 2026
4 Insider transaction Feb 27, 2026 Feb 26, 2026
4 Insider transaction Feb 27, 2026 Feb 26, 2026
4 Insider transaction Feb 27, 2026 Feb 26, 2026
4 Insider transaction Feb 27, 2026 Feb 26, 2026
8-K Current report
Results of operations, Regulation FD disclosure
Feb 26, 2026 Feb 26, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 13, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 5, 2026 —
4 Insider transaction Jan 13, 2026 Jan 9, 2026
8-K Current report
Results of operations, Regulation FD disclosure
Jan 12, 2026 Jan 12, 2026
4 Insider transaction Dec 12, 2025 Dec 11, 2025
4 Insider transaction Dec 12, 2025 Dec 10, 2025
144 Notice of proposed sale Dec 11, 2025 —
4 Insider transaction Nov 10, 2025 Nov 7, 2025
4 Insider transaction Nov 10, 2025 Nov 7, 2025
10-Q Quarterly report Nov 5, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 5, 2025 Nov 5, 2025
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
Oct 30, 2025 Oct 30, 2025
4 Insider transaction Sep 12, 2025 Sep 11, 2025
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2025 —
4 Insider transaction Aug 13, 2025 Aug 11, 2025
4 Insider transaction Aug 13, 2025 Aug 11, 2025
4 Insider transaction Aug 13, 2025 Aug 11, 2025
SCHEDULE 13G Ownership over 5% (passive) Aug 13, 2025 —
10-Q Quarterly report Aug 12, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 12, 2025 Aug 12, 2025
SCHEDULE 13G Ownership over 5% (passive) Jul 28, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Jun 24, 2025 —
4 Insider transaction Jun 23, 2025 Mar 3, 2025
4 Insider transaction Jun 23, 2025 Jun 18, 2025
4 Insider transaction Jun 23, 2025 Feb 27, 2025
4 Insider transaction Jun 23, 2025 Jun 20, 2025
4 Insider transaction Jun 23, 2025 Mar 3, 2025
4 Insider transaction Jun 23, 2025 Mar 25, 2025
4 Insider transaction Jun 23, 2025 Jun 20, 2025
4 Insider transaction Jun 23, 2025 Feb 27, 2025
4 Insider transaction Jun 23, 2025 Jun 18, 2025
4 Insider transaction Jun 23, 2025 Jun 20, 2025
8-K Current report
Bylaw or fiscal year change, Other events
Jun 20, 2025 Jun 20, 2025
424B4 Prospectus Jun 20, 2025 —
S-8 Employee stock plan registration Jun 18, 2025 —
EFFECT Filing Jun 17, 2025 —
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
3 Initial insider ownership Jun 17, 2025 Jun 17, 2025
CERT Filing Jun 17, 2025 —
S-1/A Amended registration statement Jun 16, 2025 —
8-A12B Filing Jun 13, 2025 —
CORRESP Letter to the SEC Jun 13, 2025 —
CORRESP Letter to the SEC Jun 13, 2025 —
S-1/A Amended registration statement Jun 9, 2025 —
S-1 Registration statement May 23, 2025 —
DRS/A Filing May 8, 2025 —
DRSLTR Filing May 7, 2025 —
UPLOAD Letter from the SEC Apr 16, 2025 —
DRS/A Filing Apr 4, 2025 —
DRSLTR Filing Feb 7, 2025 —
DRS/A Filing Feb 7, 2025 —
UPLOAD Letter from the SEC Jan 10, 2025 —
DRSLTR Filing Dec 20, 2024 —
DRS/A Filing Dec 20, 2024 —
UPLOAD Letter from the SEC Sep 26, 2024 —
DRSLTR Filing Sep 12, 2024 —
DRS/A Filing Sep 12, 2024 —
UPLOAD Letter from the SEC Jul 5, 2024 —
DRS Filing Jun 10, 2024 —

Showing 134 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
CAI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
TX
Headquarters
Irving, TX
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2019410

Other Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.